{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T00:45:06Z","timestamp":1775263506404,"version":"3.50.1"},"reference-count":44,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Immune checkpoint inhibitor (ICI) use has been associated with numerous autoimmune side effects, known as immune related adverse events (irAEs). Cutaneous irAEs are common and affect up to 50% of patients treated with ICIs. There have been an increasing number of cases reported in the literature regarding ICI-induced subacute cutaneous lupus erythematosus (SCLE). ICI-induced SCLE is important to recognize as it can result in a delayed and\/or prolonged skin reaction despite treatment discontinuation. We describe a patient with gastro-esophageal adenocarcinoma who developed SCLE following one cycle of nivolumab treatment. A 75-year-old man presented to our clinic with a new photo-distributed rash composed of oval scaly pink papules and plaques involving his chest and arms. Despite treatment with topical corticosteroids, he presented to the emergency department 1 week later with worsening rash. Skin biopsy showed vacuolar interface pattern, along with superficial perivascular lymphocytic infiltrate, consistent with a drug eruption. The clinicopathological presentation was consistent with ICI-induced SCLE. Nivolumab treatment was discontinued due to the severity of the rash. The rash remitted with systemic corticosteroids, high potency topical steroids, and hydroxychloroquine. Unfortunately, the patient developed intraperitoneal metastatic disease, and was enrolled in hospice care. In this paper, we highlight the importance of early identification and treatment of this irAE. A review of the literature, including a discussion on the management of ICI-induced SCLE is also provided.<\/jats:p>","DOI":"10.3389\/fmed.2024.1334718","type":"journal-article","created":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T04:23:19Z","timestamp":1706761399000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Immune checkpoint inhibitor-induced subacute cutaneous lupus erythematosus: a case report and review of the literature"],"prefix":"10.3389","volume":"11","author":[{"given":"Adam","family":"Khorasanchi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abraham M.","family":"Korman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashish","family":"Manne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexa","family":"Meara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,2,1]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","article-title":"Fundamental mechanisms of immune checkpoint blockade therapy","volume":"8","author":"Wei","year":"2018","journal-title":"Cancer Discov"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"79","DOI":"10.7497\/j.issn.2095-3941.2015.0029","article-title":"Understanding the function and dysfunction of the immune system in lung cancer: the role of immune checkpoints","volume":"12","author":"Karachaliou","year":"2015","journal-title":"Cancer Biol Med"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41368-020-0084-8","article-title":"Immune checkpoint pathways in immunotherapy for head and neck squamous cell carcinoma","volume":"12","author":"Mei","year":"2020","journal-title":"Int J Oral Sci"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"355.e21","DOI":"10.1016\/j.urolonc.2019.03.003","article-title":"Association between immune-related adverse events and prognosis in patients with metastatic renal cell carcinoma treated with nivolumab","volume":"37","author":"Ishihara","year":"2019","journal-title":"Urol Oncol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.jaad.2015.10.029","article-title":"Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: a single-institution cohort","volume":"74","author":"Hwang","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1186\/s40425-019-0805-8","article-title":"Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors","volume":"7","author":"Das","year":"2019","journal-title":"J Immunother Cancer"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"e347","DOI":"10.1111\/ajd.13538","article-title":"Subacute cutaneous lupus erythematosus induced by PD-1 inhibitor therapy: two case reports and literature review","volume":"62","author":"Diago","year":"2021","journal-title":"Australas J Dermatol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1097\/CMR.0000000000000587","article-title":"Cutaneous lupus associated with pembrolizumab therapy for advanced melanoma: a report of three cases","volume":"29","author":"Blakeway","year":"2019","journal-title":"Melanoma Res"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"e67","DOI":"10.1136\/annrheumdis-2018-213677","article-title":"Drug-induced lupus erythematosus following immunotherapy with anti-programmed death-(ligand) 1","volume":"78","author":"Michot","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1097\/CMR.0000000000000536","article-title":"Subacute cutaneous lupus erythematosus induced by nivolumab: two case reports and a literature review","volume":"29","author":"Zitouni","year":"2019","journal-title":"Melanoma Res"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.annder.2021.02.006","article-title":"Cutaneous drug-induced lupus erythematosus: clinical and immunological characteristics and update on new associated drugs","volume":"148","author":"Bataille","year":"2021","journal-title":"Ann Dermatol Venereol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1001\/jamadermatol.2018.1912","article-title":"Timing of onset of adverse cutaneous reactions associated with programmed cell death protein 1 inhibitor therapy","volume":"154","author":"Wang","year":"2018","journal-title":"JAMA Dermatol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaut.2018.07.007","article-title":"A comprehensive review of immune-mediated dermatopathology in systemic lupus erythematosus","volume":"93","author":"Li","year":"2018","journal-title":"J Autoimmun"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.berh.2013.07.008","article-title":"Cutaneous lupus erythematosus: diagnosis and treatment","volume":"27","author":"Okon","year":"2013","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s12016-017-8627-2","article-title":"The cutaneous Spectrum of lupus erythematosus","volume":"53","author":"Ribero","year":"2017","journal-title":"Clin Rev Allergy Immunol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1111\/his.14440","article-title":"Cutaneous manifestations of lupus erythematosus: a practical clinicopathological review for pathologists","volume":"80","author":"Bitar","year":"2022","journal-title":"Histopathology"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1097\/BOR.0000000000000308","article-title":"Cutaneous lupus erythematosus: updates on pathogenesis and associations with systemic lupus","volume":"28","author":"Stannard","year":"2016","journal-title":"Curr Opin Rheumatol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"987","DOI":"10.3390\/jcm12030987","article-title":"Current knowledge of the molecular pathogenesis of cutaneous lupus erythematosus","volume":"12","author":"Miyagawa","year":"2023","journal-title":"J Clin Med"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.autrev.2012.08.019","article-title":"Cutaneous lupus erythematosus: first multicenter database analysis of 1002 patients from the European Society of Cutaneous Lupus Erythematosus (EUSCLE)","volume":"12","author":"Biazar","year":"2013","journal-title":"Autoimmun Rev"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s40268-020-00320-5","article-title":"Systematic review: monoclonal antibody-induced subacute cutaneous lupus erythematosus","volume":"20","author":"Bolton","year":"2020","journal-title":"Drugs R D"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1097\/BOR.0000000000000522","article-title":"Drug-induced lupus erythematosus: an update on drugs and mechanisms","volume":"30","author":"He","year":"2018","journal-title":"Curr Opin Rheumatol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1001\/jamadermatol.2013.4957","article-title":"Subacute cutaneous lupus erythematosus induced by chemotherapy: gemcitabine as a causative agent","volume":"149","author":"Wiznia","year":"2013","journal-title":"JAMA Dermatol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1177\/0961203310370349","article-title":"Drug-induced subacute cutaneous lupus erythematosus","volume":"19","author":"Callen","year":"2010","journal-title":"Lupus"},{"key":"ref24","author":"Heymann","year":"2023"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"e152","DOI":"10.1111\/ajd.12681","article-title":"Subacute cutaneous lupus erythematosus induced by nivolumab","volume":"59","author":"Liu","year":"2018","journal-title":"Australas J Dermatol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1016\/j.jaad.2020.10.054","article-title":"De novo cutaneous connective tissue disease temporally associated with immune checkpoint inhibitor therapy: a retrospective analysis","volume":"84","author":"Bui","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1111\/bjd.17245","article-title":"Subacute cutaneous lupus erythematosus and dermatomyositis associated with anti-programmed cell death 1 therapy","volume":"181","author":"Marano","year":"2019","journal-title":"Br J Dermatol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1111\/ced.14449","article-title":"De novo subacute cutaneous lupus erythematosus-like eruptions in the setting of programmed death-1 or programmed death ligand-1 inhibitor therapy: clinicopathological correlation","volume":"46","author":"Bui","year":"2021","journal-title":"Clin Exp Dermatol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1177\/0961203320983448","article-title":"Onset of subacute cutaneous lupus erythematosus after the initiation of immune checkpoint inhibitor therapy of cancer","volume":"30","author":"Gambichler","year":"2021","journal-title":"Lupus"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1111\/cup.13059","article-title":"Lupus-like cutaneous reaction following pembrolizumab: an immune-related adverse event associated with anti-PD-1 therapy","volume":"45","author":"Shao","year":"2018","journal-title":"J Cutan Pathol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"51","DOI":"10.2147\/CCID.S344445","article-title":"Subacute cutaneous lupus erythematosus-like eruption induced by Durvalumab: a case report and literature review","volume":"15","author":"Pratumchart","year":"2022","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"821","DOI":"10.5070\/D32510045821","article-title":"Widespread subacute cutaneous lupus erythematosus in a patient receiving checkpoint inhibitor immunotherapy with ipilimumab and nivolumab","volume":"25","author":"Kosche","year":"2019","journal-title":"Dermatol Online J"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.ejca.2020.12.017","article-title":"Late onset of subacute cutaneous lupus erythematosus following pembrolizumab therapy","volume":"145","author":"Andersson","year":"2021","journal-title":"Eur J Cancer"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"e217","DOI":"10.1111\/1346-8138.15316","article-title":"Subacute cutaneous lupus erythematosus with melanocyte elimination induced by pembrolizumab","volume":"47","author":"Ogawa-Momohara","year":"2020","journal-title":"J Dermatol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1111\/cup.12858","article-title":"Diverse types of dermatologic toxicities from immune checkpoint blockade therapy","volume":"44","author":"Curry","year":"2017","journal-title":"J Cutan Pathol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1159\/000455014","article-title":"Adverse renal effects of immune checkpoint inhibitors: a narrative review","volume":"45","author":"Wanchoo","year":"2017","journal-title":"Am J Nephrol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.ejca.2019.08.030","article-title":"Nivolumab-related mucous membrane pemphigoid","volume":"121","author":"Sibaud","year":"2019","journal-title":"Eur J Cancer"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1016\/j.jaad.2019.08.045","article-title":"BP180-specific IgG is associated with skin adverse events, therapy response, and overall survival in non-small cell lung cancer patients treated with checkpoint inhibitors","volume":"82","author":"Hasan Ali","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/j.jaad.2020.03.132","article-title":"Immune checkpoint inhibitor-related dermatologic adverse events","volume":"83","author":"Geisler","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.clindermatol.2020.06.011","article-title":"Cutaneous immune-related adverse events to checkpoint inhibitors","volume":"38","author":"Malviya","year":"2020","journal-title":"Clin Dermatol"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.clindermatol.2022.07.007","article-title":"Subacute cutaneous lupus erythematosus: A facultative paraneoplastic dermatosis","volume":"40","author":"Lazar","year":"2022","journal-title":"Clin Dermatol"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.jdcr.2022.02.001","article-title":"Paraneoplastic subacute cutaneous lupus erythematosus with mucositis","volume":"22","author":"Abbott","year":"2022","journal-title":"JAAD Case Rep"},{"key":"ref43","year":"2017"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1334718\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T04:23:23Z","timestamp":1706761403000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1334718\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,1]]},"references-count":44,"alternative-id":["10.3389\/fmed.2024.1334718"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2024.1334718","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,1]]},"article-number":"1334718"}}